NC
VYGR icon

nVerses Capital’s Voyager Therapeutics VYGR Stock Holding History

nVerses Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,631
Closed -$48.8K – 543
2026
Q1 		$48.8K Buy
+12,631
New +$49.7K 0.04% 340
2024
Q4 		– Sell
-1,900
Closed -$11.1K – 884
2024
Q3 		$11.1K Buy
1,900
+1,800
+1,800% +$13.1K 0.01% 877
2024
Q2 		$791 Buy
+100
New +$838 ﹤0.01% 979

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

nVerses Capital's VYGR Position: Q2 2026 in Review

nVerses Capital sold out of Voyager Therapeutics (VYGR) in Q2 2026, closing a stake of 12,631 shares — an estimated $48.8K sold.

nVerses Capital first reported a position in VYGR in Q2 2024 and held it in 3 quarters. The position peaked at $48.8K in Q1 2026. 89 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • nVerses Capital reported no remaining Voyager Therapeutics position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 12,631 Voyager Therapeutics shares in Q2 2026, an estimated $48.8K.
  • nVerses Capital first reported a position in Voyager Therapeutics in Q2 2024 and held it in 3 quarters.
  • nVerses Capital's Voyager Therapeutics position peaked at $48.8K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.